

Dr Morris' publications and research information

Publications

Dr Morris has written and edited the 5th edition of The UK practical Radiotherapy planning book, written 4 other book chapters and published 12 original peer review articles.

Examples:

- Barret, Dobbs, Morris & Roakes. Practical Radiotherapy Planning. 5th Edition 2009. Hodder Arnold.
- Morris S L, Dobbs H J. Principles of External Beam Radiotherapy Planning Chapter. 5th edition Price & Sikora.
- Morris SL, Whittaker S, Spittle M. Non Melanoma Skin Cancer Chapter. 5th Edition Price & Sikora
- Morris SL, Low SH, A'Hern RP, Eisen TG, Gore ME, Nutting CM, Harrington KJ. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma British Journal of Cancer 2004 Aug 31; 91 (5) : 829-33
- Morris SL, Parker C, Huddart R, Horwich A, Dearnaley D. Current Opinion on adjuvant and salvage treatment after radical prostatectomy – A UK Survey. Clinical Oncology June 2004;16:227-282
- Acher PL, Popert J, Potters L, Morris SL, Beaney RP. Permanent prostate brachytherapy: dosimetric results and analysis of a learning curve with a dynamic dose feedback technique. International Journal of Radiation Oncology, Biology, Physics 2006 Jul 1;65(3):694-8

Current open trials:

- **RADICALS** - This randomized phase III trial is studying how well giving radiation therapy together with androgen deprivation therapy works in treating patients who have undergone surgery for prostate cancer
- **STAMPEDE** - This randomized phase III trial is designed to assess the safety and efficacy of 3 very different drugs for the treatment of locally advanced or metastatic prostate cancer. These drugs are docetaxel (chemotherapy), zoledronic acid (bisphosphonate) and celecoxib (cox-2-inhibitor) and are given in various combinations to patients starting long-term hormone therapy.
- **FORT** - This randomised phase III trial is comparing low dose radiotherapy with standard radiotherapy for people with follicular lymphoma or marginal zone lymphoma
- **GEMBEX** - This phase II trial is looking at gemcitabine chemotherapy and bexatone for cutaneous T cell lymphoma that has come back or stopped responding to treatment.